U.S. License Holder:
Eli Lilly and Co.
Date of License:
CYRAMZA (ramucirumab) is a human vascular endothelial growth factor receptor 2 antagonist indicated:
As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy;
In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.